Sidoti Csr Has Negative Forecast for USNA FY2024 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Sidoti Csr lowered their FY2024 EPS estimates for shares of USANA Health Sciences in a note issued to investors on Wednesday, October 23rd. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $2.45 for the year, down from their previous forecast of $2.48. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.50 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2024 earnings at $0.49 EPS, Q1 2025 earnings at $0.73 EPS, Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.64 EPS, Q4 2025 earnings at $0.75 EPS, FY2025 earnings at $2.74 EPS, Q1 2026 earnings at $0.82 EPS, Q2 2026 earnings at $0.74 EPS, Q3 2026 earnings at $0.77 EPS and FY2026 earnings at $3.20 EPS.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. The company had revenue of $200.22 million for the quarter, compared to analyst estimates of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. During the same quarter in the previous year, the business earned $0.59 earnings per share.

USNA has been the topic of several other reports. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th. DA Davidson dropped their price target on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday.

USANA Health Sciences Trading Up 3.4 %

NYSE USNA opened at $37.81 on Thursday. The firm has a market capitalization of $720.28 million, a PE ratio of 13.36, a price-to-earnings-growth ratio of 1.15 and a beta of 0.89. The business’s 50-day moving average price is $37.96 and its two-hundred day moving average price is $42.51. USANA Health Sciences has a 12 month low of $34.15 and a 12 month high of $54.81.

Insider Buying and Selling at USANA Health Sciences

In other news, Director Gilbert A. Fuller sold 674 shares of USANA Health Sciences stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director John Turman Fleming sold 1,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the transaction, the director now owns 2,503 shares in the company, valued at $111,208.29. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilbert A. Fuller sold 674 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,940 shares of company stock valued at $311,670. 0.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

Institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. increased its position in USANA Health Sciences by 13.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company’s stock valued at $4,702,000 after buying an additional 14,756 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in USANA Health Sciences by 14,068.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock valued at $1,472,000 after acquiring an additional 38,547 shares during the period. Creative Planning bought a new stake in shares of USANA Health Sciences during the third quarter valued at approximately $394,000. Exchange Traded Concepts LLC raised its position in shares of USANA Health Sciences by 4.4% during the third quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock worth $292,000 after purchasing an additional 322 shares during the period. Finally, Unison Advisors LLC bought a new position in shares of USANA Health Sciences in the 3rd quarter worth $683,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.